{"id":"comparison-of-risperidone-and-aripiprazole","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Weight gain"},{"rate":"15-25","effect":"Metabolic syndrome / dyslipidemia"},{"rate":"5-15","effect":"Extrapyramidal symptoms (EPS)"},{"rate":"risperidone higher than aripiprazole","effect":"Prolactin elevation"},{"rate":"10-20","effect":"Sedation"},{"rate":"5-10","effect":"Akathisia"},{"rate":"5-10","effect":"Orthostatic hypotension"}]},"_chembl":{"chemblId":"CHEMBL2219425","moleculeType":"Small molecule","molecularWeight":"660.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Risperidone is a typical second-generation antipsychotic that antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways to reduce psychotic symptoms, while also blocking 5-HT2A receptors. Aripiprazole differs by functioning as a partial agonist at D2 receptors, providing dopaminergic stabilization rather than pure antagonism. Both agents are used to treat psychotic and mood disorders, but their distinct mechanisms result in different efficacy and side effect profiles.","oneSentence":"This is a comparative analysis of two marketed antipsychotics with different mechanisms: risperidone blocks dopamine D2 and serotonin 5-HT2A receptors, while aripiprazole acts as a dopamine D2 partial agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:47.630Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder (acute mania and maintenance)"},{"name":"Major depressive disorder (adjunctive treatment with aripiprazole)"},{"name":"Irritability associated with autism spectrum disorder (aripiprazole)"}]},"trialDetails":[{"nctId":"NCT04903353","phase":"PHASE4","title":"Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-02-01","conditions":"Weight Gain, Autism Spectrum Disorder, Medication Side Effect","enrollment":31},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT03883204","phase":"PHASE4","title":"Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up","status":"UNKNOWN","sponsor":"Fundación Marques de Valdecilla","startDate":"2015-01-01","conditions":"Schizophrenia, Psychotic Disorders, Psychosis","enrollment":115},{"nctId":"NCT02191358","phase":"","title":"YouScript IMPACT Registry","status":"COMPLETED","sponsor":"Genelex Corporation","startDate":"2014-10","conditions":"Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation","enrollment":800},{"nctId":"NCT00320671","phase":"PHASE4","title":"Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2005-12","conditions":"Schizophrenia","enrollment":198},{"nctId":"NCT02334904","phase":"","title":"Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2014-07","conditions":"First-Episode Psychosis, Bipolar Disorder","enrollment":60},{"nctId":"NCT01739127","phase":"","title":"Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2012-11","conditions":"Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X","enrollment":83},{"nctId":"NCT00177164","phase":"PHASE3","title":"Risperdal Consta for Bipolar Disorder","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-11","conditions":"Bipolar I Disorder","enrollment":50},{"nctId":"NCT01157351","phase":"PHASE4","title":"15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2010-05","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT01822730","phase":"PHASE4","title":"A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis","status":"COMPLETED","sponsor":"Wei Hao","startDate":"2013-02","conditions":"Methamphetamine Dependence","enrollment":120},{"nctId":"NCT01813643","phase":"PHASE4","title":"A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis","status":"TERMINATED","sponsor":"Wei Hao","startDate":"2012-07","conditions":"Methamphetamine Dependence","enrollment":50},{"nctId":"NCT00466310","phase":"PHASE1","title":"Metabolic Signatures and Biomarkers in Schizophrenia","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-02","conditions":"Schizophrenia","enrollment":71},{"nctId":"NCT01109147","phase":"PHASE4","title":"Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients","status":"COMPLETED","sponsor":"Qualissima","startDate":"2010-12","conditions":"Schizophrenia, Undifferentiated Type","enrollment":67},{"nctId":"NCT01193166","phase":"PHASE4","title":"Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital","status":"WITHDRAWN","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2010-08","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT01607762","phase":"PHASE1","title":"A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-02","conditions":"Healthy","enrollment":31},{"nctId":"NCT01129674","phase":"PHASE2, PHASE3","title":"A Long-Term, Open-Label, Study on Schizophrenia","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2010-06","conditions":"Schizophrenia","enrollment":1210},{"nctId":"NCT00299702","phase":"PHASE4","title":"Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-02","conditions":"Schizophrenia, Psychotic Disorders","enrollment":355},{"nctId":"NCT00573716","phase":"","title":"Comparison of Bone Mineral Density Changes During Tx With Risperidone or Aripiprazole in Adolescents","status":"COMPLETED","sponsor":"Creighton University","startDate":"2006-10","conditions":"Psychiatry","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Comparison of Risperidone and Aripiprazole","genericName":"Comparison of Risperidone and Aripiprazole","companyName":"Vanderbilt University Medical Center","companyId":"vanderbilt-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a comparative analysis of two marketed antipsychotics with different mechanisms: risperidone blocks dopamine D2 and serotonin 5-HT2A receptors, while aripiprazole acts as a dopamine D2 partial agonist. Used for Schizophrenia, Bipolar disorder (acute mania and maintenance), Major depressive disorder (adjunctive treatment with aripiprazole).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}